Label expansion for argenx lifts Vyvgart’s growth prospects

Growth of argenx’s Vyvgart could get another shot in the arm after the Dutch biotech received an FDA label expansion for the FCRN inhibitor to treat CIDP. 

First approved in 2021 and launched in 1Q22, Vyvgart efgartigimod and its subcutaneous formulation Vyvgart Hytrulo have been the growth engine for argenx S.E. (Euronext:ARGX; NASDAQ:ARGX), with sales for its first indication of generalized myasthenia gravis (gMG) hitting more than $1.2 billion in just its second year on the market...